For more information, visit https://www.avient.com. Investor Relations Contact: Giuseppe (Joe) Di Salvo, Vice President, Treasurer and Investor Relations, Avient Corporation, +1 440-930-1921, giuseppe.disalvo@avient.com, or Media Contact: Kyle G. Investor Contacts

Such notification shall contain the details of a contact point where more information can be obtained, a description of the nature of the breach (including, where possible, categories and approximate number of data subjects and personal data records concerned), its likely consequences and the measures taken or proposed to address the breach including, where appropriate, measures to mitigate its possible adverse effects. The data importer shall inform data subjects in a transparent and easily accessible format, through individual notice or on its website, of a contact point authorised to handle complaints. The data importer shall inform data subjects in a transparent and easily accessible format, through individual notice or on its website, of a contact point authorised to handle complaints.

MEVOPUR COLORANTS • Standard colors in PP and PE to shorten time-to-market • Custom colors matched to Pantone, RAL or other color reference • White colorants for pharmaceutical packaging for LDPE, HDPE and PP with opacity to reach USP chapter MEVOPUR FUNCTIONAL ADDITIVES • Antistatic formulation with good flow/impact for injection molding • Amide- and amine-free antistatic for film in contact with API (Active Pharmaceutical Ingredients) • UV blocking for transparent PP and PE packaging to meet USP chapter • Non-migrating friction reduction/processing aid for PE and PP • Laser marking/welding additive for fast, reliable marking/assembly • MVTR (Moisture Vapor Transmission Rate) reduction for HDPE to improve shelf-life • Thermal protection of the polymer during processing • Gamma/e-beam sterilization protection for PP (up to 50kGy) with color compensation for reduced yellowing REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Bormed™ is a registered trademark of Borealis Healthcare use limitations apply—see below. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Visit www.avient.com to learn more.   Media Contact Crandall Turner Avient Corporation crandall.turner@avient.com   Media Relations Contacts

Visit www.avient.com to learn more.   Media Contact Crandall Turner Avient Corporation crandall.turner@avient.com  Media Relations Contacts

Visit www.avient.com to learn more.   Media Contact Nicole DeChant Avient Corporation nicole.dechant@avient.com Media Relations Contacts

Visit www.avient.com to learn more.   Media Contact Nicole DeChant Avient Corporation nicole.dechant@avient.com Media Relations Contacts

Visit www.avient.com to learn more.   Media Contact Nicole DeChant Avient Corporation nicole.dechant@avient.com Media Relations Contacts

KEY CHARACTERISTICS • Manufactured under ISO 13485 procedures • Documented change control beyond CAS number, reducing risk of change • Can be used on common injection molding and extrusion machines—set-up support by a technical assistance team • Available for use in polyolefins, styrenics and copolymers • Can be combined with colorants REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP and (incl. class VI) - European Pharmacopeia, monograph 3.1.3/ 3.1.5 (polyolefin packaging materials) - USP (polyethylene) - Elemental impurities as per ICH Q3D • Registered Drug Master File (Type III) and/or Device Master File • Food contact according to USA FDA and EU norms APPLICATION BULLETIN Sustainability Spotlight Healthcare use limitations apply—see below. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Microsoft PowerPoint - AVNT M11 Investor Presentation AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) N O V E M B E R 2 0 2 4 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. A reconciliation of each historical non-GAAP financial measure with the most directly comparable GAAP financial measure is attached to this presentation which is posted on our website at www.avient.com. EBITDA $130 million +6% (+7% ex FX)Net Sales $815 million +8% (+8.5% ex FX) Net Sales $815 million +8% (+8.5% ex FX) Q 3 2 0 2 4 R E S U L T S TOTAL COMPANY ( Q 3 2 0 2 4 P E R F O R M A N C E V S Q 3 2 0 2 3 ) $754 $815 Q3 23 Q3 24 $123 $130 Q3 23 Q3 24 Sales Adjusted EBITDA (in millions) $0.57 $0.65 Q3 23 Q3 24 (in millions) Adjusted EBITDA Adjusted EPS 8 + 8% (+8.5% excluding FX) + 6% (+7% excluding FX) + 14% (+16% excluding FX) Sales 9 Q3 2 024 RESULTS – ORGA NI C REVENUE GROW TH BY REGI ON VS PY 9 US & Canada Latin America EMEA Asia +9% +5% +11% +27% Avient ex.